Sanofi (SNY) Gross Margin (2009 - 2026)

Sanofi (SNY) posted Gross Margin of 80.05% for Q2 2026, up 3.78% sequentially from 77.13% in Q1 2026, and up 257.0% YoY from 22.42% in Q2 2025.

Sanofi (SNY) Gross Margin (2009 - 2026) Analysis & Trends

Sanofi has reported Gross Margin for 18 years, with the latest figure at 80.05% in Q2 2026.

Quarterly Gross Margin rose 257.0% year-over-year to 80.05% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 77.65% (down 64.0% YoY) and the FY2025 annual result came in at 77.17%, up 151.0% from the prior year.
Gross Margin grew to 80.05% in Q2 2026 per SNY's latest filing, from 77.13% in the prior quarter.
Over five years, Gross Margin peaked at 83.31% in Q4 2024 and troughed at 74.03% in Q3 2023.
A 5-year average of 76.79% and a median of 76.38% in 2023 frame the typical range for Gross Margin.
The sharpest annual moves came in 2024 and 2025: Gross Margin surged 665 bps in 2024, then sank 165 bps in 2025.
Over 5 years, Gross Margin stood at 74.28% in 2022, then advanced by 3 bps to 76.66% in 2023, then rose by 9 bps to 83.31% in 2024, then fell by 2 bps to 81.66% in 2025, then retreated by 2 bps to 80.05% in 2026.
According to Business Quant data, Gross Margin over the past three periods registered 80.05%, 77.13%, and 81.66% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	68.19%
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	74.74%
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	73.54%
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	78.02%
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	83.60%
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	72.04%
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	79.76%
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	72.78%
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	73.05%
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	80.05%

Download Data